Interleukin-10 delivery via mesenchymal stem cells: A novel gene therapy approach to prevent lung ischemia-reperfusion injury

Eddie Manning, Si Pham, Sen Li, Roberto I Vazquez-Padron, James Mathew, Phillip Ruiz, Shashikumar K. Salgar

Research output: Contribution to journalArticle

58 Citations (Scopus)

Abstract

Ischemia-reperfusion (IR) injury is an important cause of primary graft failure in lung transplantation. In this study, viral interleukin-10 (vIL-10)-engineered mesenchymal stem cells (MSCs) were tested for their ability to prevent lung IR injury. Bone marrow-derived MSCs were transduced with rvIL-10-retrovirus. After 120min of warm left lung ischemia, rats received ∼15×106 vIL-10-engineered MSCs (MSC-vIL-10), empty vector-engineered MSCs (MSC-vec), or saline intravenously. Mean blood oxygenation (PaO2/FiO2 ratio, mmHg) was measured at 4hr, 24hr, 72hr, and 7 days. As early as 4hr post-IR injury with MSC-vIL-10 treatment, blood oxygenation was significantly (p<0.05) improved (319±94; n=7) compared with untreated (saline) controls (63±19; n=6). At 24hr post-IR injury, in the MSC-vIL-10-treated group there was a further increase in blood oxygenation (353±105; n=10) compared with the MSC-vec group (138±86; n=9) and saline group (87±39; n=10). By 72hr, oxygenation reached normal (475±55; n=9) in the MSC-vIL-10-treated group but not in the saline-treated and MSC-vec-treated groups. At 4hr after IR injury, lungs with MSC-vIL10 treatment had a lower (p<0.05) injury score (0.9±0.4) compared with lungs of the untreated (saline) group (2.5±1.4) or MSC-vec-treated group (2±0.4). Lung microvascular permeability and wet-to-dry weight ratios were markedly lower in the MSC-vIL10 group compared with untreated (saline) controls. ISOL (in situ oligonucleotide ligation for DNA fragmentation detection) and caspase-3 staining demonstrated significantly (p<0.05) fewer apoptotic cells in MSC-vIL10-treated lungs. Animals that received MSC-vIL10 therapy had fewer (p<0.05) CD4+ and CD8+ T cells in bronchoalveolar lavage fluid compared with untreated control animals. A therapeutic strategy using vIL-10-engineered MSCs to prevent IR injury in lung transplantation seems promising.

Original languageEnglish
Pages (from-to)713-727
Number of pages15
JournalHuman Gene Therapy
Volume21
Issue number6
DOIs
StatePublished - Jun 1 2010

Fingerprint

Reperfusion Injury
Mesenchymal Stromal Cells
Genetic Therapy
Interleukin-10
Lung
Lung Transplantation
Bronchoalveolar Lavage Fluid
Capillary Permeability
DNA Fragmentation
Retroviridae
Cell- and Tissue-Based Therapy
Oligonucleotides
Caspase 3
Ligation

ASJC Scopus subject areas

  • Molecular Medicine
  • Molecular Biology
  • Genetics

Cite this

Interleukin-10 delivery via mesenchymal stem cells : A novel gene therapy approach to prevent lung ischemia-reperfusion injury. / Manning, Eddie; Pham, Si; Li, Sen; Vazquez-Padron, Roberto I; Mathew, James; Ruiz, Phillip; Salgar, Shashikumar K.

In: Human Gene Therapy, Vol. 21, No. 6, 01.06.2010, p. 713-727.

Research output: Contribution to journalArticle

@article{a674ef2bd0954c47b7d85b75d164ec3a,
title = "Interleukin-10 delivery via mesenchymal stem cells: A novel gene therapy approach to prevent lung ischemia-reperfusion injury",
abstract = "Ischemia-reperfusion (IR) injury is an important cause of primary graft failure in lung transplantation. In this study, viral interleukin-10 (vIL-10)-engineered mesenchymal stem cells (MSCs) were tested for their ability to prevent lung IR injury. Bone marrow-derived MSCs were transduced with rvIL-10-retrovirus. After 120min of warm left lung ischemia, rats received ∼15×106 vIL-10-engineered MSCs (MSC-vIL-10), empty vector-engineered MSCs (MSC-vec), or saline intravenously. Mean blood oxygenation (PaO2/FiO2 ratio, mmHg) was measured at 4hr, 24hr, 72hr, and 7 days. As early as 4hr post-IR injury with MSC-vIL-10 treatment, blood oxygenation was significantly (p<0.05) improved (319±94; n=7) compared with untreated (saline) controls (63±19; n=6). At 24hr post-IR injury, in the MSC-vIL-10-treated group there was a further increase in blood oxygenation (353±105; n=10) compared with the MSC-vec group (138±86; n=9) and saline group (87±39; n=10). By 72hr, oxygenation reached normal (475±55; n=9) in the MSC-vIL-10-treated group but not in the saline-treated and MSC-vec-treated groups. At 4hr after IR injury, lungs with MSC-vIL10 treatment had a lower (p<0.05) injury score (0.9±0.4) compared with lungs of the untreated (saline) group (2.5±1.4) or MSC-vec-treated group (2±0.4). Lung microvascular permeability and wet-to-dry weight ratios were markedly lower in the MSC-vIL10 group compared with untreated (saline) controls. ISOL (in situ oligonucleotide ligation for DNA fragmentation detection) and caspase-3 staining demonstrated significantly (p<0.05) fewer apoptotic cells in MSC-vIL10-treated lungs. Animals that received MSC-vIL10 therapy had fewer (p<0.05) CD4+ and CD8+ T cells in bronchoalveolar lavage fluid compared with untreated control animals. A therapeutic strategy using vIL-10-engineered MSCs to prevent IR injury in lung transplantation seems promising.",
author = "Eddie Manning and Si Pham and Sen Li and Vazquez-Padron, {Roberto I} and James Mathew and Phillip Ruiz and Salgar, {Shashikumar K.}",
year = "2010",
month = "6",
day = "1",
doi = "10.1089/hum.2009.147",
language = "English",
volume = "21",
pages = "713--727",
journal = "Human Gene Therapy",
issn = "1043-0342",
publisher = "Mary Ann Liebert Inc.",
number = "6",

}

TY - JOUR

T1 - Interleukin-10 delivery via mesenchymal stem cells

T2 - A novel gene therapy approach to prevent lung ischemia-reperfusion injury

AU - Manning, Eddie

AU - Pham, Si

AU - Li, Sen

AU - Vazquez-Padron, Roberto I

AU - Mathew, James

AU - Ruiz, Phillip

AU - Salgar, Shashikumar K.

PY - 2010/6/1

Y1 - 2010/6/1

N2 - Ischemia-reperfusion (IR) injury is an important cause of primary graft failure in lung transplantation. In this study, viral interleukin-10 (vIL-10)-engineered mesenchymal stem cells (MSCs) were tested for their ability to prevent lung IR injury. Bone marrow-derived MSCs were transduced with rvIL-10-retrovirus. After 120min of warm left lung ischemia, rats received ∼15×106 vIL-10-engineered MSCs (MSC-vIL-10), empty vector-engineered MSCs (MSC-vec), or saline intravenously. Mean blood oxygenation (PaO2/FiO2 ratio, mmHg) was measured at 4hr, 24hr, 72hr, and 7 days. As early as 4hr post-IR injury with MSC-vIL-10 treatment, blood oxygenation was significantly (p<0.05) improved (319±94; n=7) compared with untreated (saline) controls (63±19; n=6). At 24hr post-IR injury, in the MSC-vIL-10-treated group there was a further increase in blood oxygenation (353±105; n=10) compared with the MSC-vec group (138±86; n=9) and saline group (87±39; n=10). By 72hr, oxygenation reached normal (475±55; n=9) in the MSC-vIL-10-treated group but not in the saline-treated and MSC-vec-treated groups. At 4hr after IR injury, lungs with MSC-vIL10 treatment had a lower (p<0.05) injury score (0.9±0.4) compared with lungs of the untreated (saline) group (2.5±1.4) or MSC-vec-treated group (2±0.4). Lung microvascular permeability and wet-to-dry weight ratios were markedly lower in the MSC-vIL10 group compared with untreated (saline) controls. ISOL (in situ oligonucleotide ligation for DNA fragmentation detection) and caspase-3 staining demonstrated significantly (p<0.05) fewer apoptotic cells in MSC-vIL10-treated lungs. Animals that received MSC-vIL10 therapy had fewer (p<0.05) CD4+ and CD8+ T cells in bronchoalveolar lavage fluid compared with untreated control animals. A therapeutic strategy using vIL-10-engineered MSCs to prevent IR injury in lung transplantation seems promising.

AB - Ischemia-reperfusion (IR) injury is an important cause of primary graft failure in lung transplantation. In this study, viral interleukin-10 (vIL-10)-engineered mesenchymal stem cells (MSCs) were tested for their ability to prevent lung IR injury. Bone marrow-derived MSCs were transduced with rvIL-10-retrovirus. After 120min of warm left lung ischemia, rats received ∼15×106 vIL-10-engineered MSCs (MSC-vIL-10), empty vector-engineered MSCs (MSC-vec), or saline intravenously. Mean blood oxygenation (PaO2/FiO2 ratio, mmHg) was measured at 4hr, 24hr, 72hr, and 7 days. As early as 4hr post-IR injury with MSC-vIL-10 treatment, blood oxygenation was significantly (p<0.05) improved (319±94; n=7) compared with untreated (saline) controls (63±19; n=6). At 24hr post-IR injury, in the MSC-vIL-10-treated group there was a further increase in blood oxygenation (353±105; n=10) compared with the MSC-vec group (138±86; n=9) and saline group (87±39; n=10). By 72hr, oxygenation reached normal (475±55; n=9) in the MSC-vIL-10-treated group but not in the saline-treated and MSC-vec-treated groups. At 4hr after IR injury, lungs with MSC-vIL10 treatment had a lower (p<0.05) injury score (0.9±0.4) compared with lungs of the untreated (saline) group (2.5±1.4) or MSC-vec-treated group (2±0.4). Lung microvascular permeability and wet-to-dry weight ratios were markedly lower in the MSC-vIL10 group compared with untreated (saline) controls. ISOL (in situ oligonucleotide ligation for DNA fragmentation detection) and caspase-3 staining demonstrated significantly (p<0.05) fewer apoptotic cells in MSC-vIL10-treated lungs. Animals that received MSC-vIL10 therapy had fewer (p<0.05) CD4+ and CD8+ T cells in bronchoalveolar lavage fluid compared with untreated control animals. A therapeutic strategy using vIL-10-engineered MSCs to prevent IR injury in lung transplantation seems promising.

UR - http://www.scopus.com/inward/record.url?scp=77954982590&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77954982590&partnerID=8YFLogxK

U2 - 10.1089/hum.2009.147

DO - 10.1089/hum.2009.147

M3 - Article

C2 - 20102275

AN - SCOPUS:77954982590

VL - 21

SP - 713

EP - 727

JO - Human Gene Therapy

JF - Human Gene Therapy

SN - 1043-0342

IS - 6

ER -